SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

SRT3

228.6

-0.87%↓

GXI

55.35

+3.07%↑

ICAD

21.04

-0.38%↓

Search

BioMerieux

Gesloten

SectorGezondheidszorg

115.5 1.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

113.8

Max

115.8

Belangrijke statistieken

By Trading Economics

Inkomsten

215M

Verkoop

785M

K/W

Sectorgemiddelde

31.236

57.333

Dividendrendement

0.79

Winstmarge

11.32

Werknemers

14,147

EBITDA

161M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+16.61% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.79%

2.63%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-117M

13B

Vorige openingsprijs

114.01

Vorige sluitingsprijs

115.5

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

BioMerieux Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 apr 2025, 08:49 UTC

Belangrijke Marktbewegers

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Peer Vergelijking

Prijswijziging

BioMerieux Prognose

Koersdoel

By TipRanks

16.61% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 133.17 EUR  16.61%

Hoogste 140 EUR

Laagste 127 EUR

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioMerieux - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technische score

By Trading Central

113.8 / 118.9Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.